title: Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR--phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucémies (GEIL).
abstract: The immunophenotype of blast cells was investigated in a multicentric study of 154 adult acute myeloblastic leukemias (AMLs). A panel of 27 monoclonal antibodies (MoAbs) was tested in indirect immunofluorescence. Expression of CD14 (UCHM1), CD19 (SB4), CD36 (OKM5), and HLA-DR were associated with higher mean leucocyte counts. CD14 expression correlated with low hemoglobin level and the absence of CD33 (MY9) with low platelet counts. Extramedullary disease was associated with CD16 (Leu11b) and HLA-DR antigen positivity. The study of relationships between surface markers and FAB criteria confirmed the predominant expression of CD14 in the M5 sub-group (p less than 0.000001) and the association of CD19 and CD36 with monocytic M4/M5 subgroups (respectively p less than 0.00002 and p less than 0.000001). All patients received an induction therapy including an anthracycline and cytarabine. The median follow-up was 13 months. The achievement of complete remission (CR) was inversely correlated with CD34 (B13C5) and CD19 expression: CR was obtained in 31 of 59 (53%) CD34-positive AML versus 64 of 75 (85%) CD34-negative cases (p less than 0.0001) and 11 of 24 (46%) CD19-positive versus 95 of 122 (78%) CD19-negative cases (p less than 0.01). In univariate analysis, a longer survival was associated with CD33 expression and the combined phenotypes CD36+/CD19- and CD16+/CD14-. Conversely, the CD18(IOT18)+/CDw65(VIM2)- phenotype was related to shorter survival. The expression of CD19, of CD34, and of the combined phenotype CD14+/DR--correlated with shorter survival as demonstrated both in univariate and multivariate analysis (p less than 0.03 in each case in multivariate analysis).
authors.affiliation: Unité d'Hématologie Clinique, C.H.U. Le Bocage, Dijon, France.
authors.forename: E
authors.initials: E
authors.lastname: Solary
authors.forename: R O
authors.initials: RO
authors.lastname: Casasnovas
authors.forename: L
authors.initials: L
authors.lastname: Campos
authors.forename: M C
authors.initials: MC
authors.lastname: Béné
authors.forename: G
authors.initials: G
authors.lastname: Faure
authors.forename: P
authors.initials: P
authors.lastname: Maingon
authors.forename: A
authors.initials: A
authors.lastname: Falkenrodt
authors.forename: B
authors.initials: B
authors.lastname: Lenormand
authors.forename: N
authors.initials: N
authors.lastname: Genetet
mesh_terms: D015703:Antigens, CD / Q000032:analysis; D018941:Antigens, CD19; D018952:Antigens, CD34; D000944:Antigens, Differentiation, B-Lymphocyte / Q000032:analysis; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology*; D006684:HLA-DR Antigens / Q000032:analysis; D016130:Immunophenotyping; D015470:Leukemia, Myeloid, Acute / Q000145:classification / Q000276:immunology* / Q000401:mortality; D018950:Lipopolysaccharide Receptors; D015337:Multicenter Studies as Topic; D011379:Prognosis; D011446:Prospective Studies
chemical_list: D015703:Antigens, CD; D018941:Antigens, CD19; D018952:Antigens, CD34; D000944:Antigens, Differentiation, B-Lymphocyte; D015214:Antigens, Differentiation, Myelomonocytic; D000945:Antigens, Differentiation, T-Lymphocyte; D006684:HLA-DR Antigens; D018950:Lipopolysaccharide Receptors